Gevokizumab is a monoclonal antibody targeting interleukin 1_ (IL-1_), which is a pro-inflammatory cytokine. Gevokizumab has been used in the research of type 2 diabetes mellitus, scleritis and various cancers.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.